Tidepath

Growth-hormone peptides

Ipamorelin

Prompts growth-hormone release like its neighbours, through a different receptor.

Status
Not approved by the FDA.
Routes we have on file
By injection
Where doses come from
No checked dose range
Half-life
About 2 hours after a 15-minute infusion into a vein

What it is

Ipamorelin tells the pituitary to release growth hormone by acting on the ghrelin receptor, the receptor for the hormone ghrelin. That's a separate route to the same release that GHRH analogues (copies of GHRH, the hormone that tells the pituitary to release growth hormone), such as sermorelin, trigger.

What makes it distinct

It contains unnatural amino acids, ones the body doesn't use to build its own proteins. The FDA says compounded ipamorelin (mixed from its ingredients by a pharmacist or doctor) given certain ways may carry a risk of immune reactions (immunogenicity), because the peptide may clump together (aggregation) or carry impurities related to it. It also says it hasn't found safety information for certain ways of injecting it other than into a vein. So the FDA lacks enough information to know whether ipamorelin given those ways would harm people.

Open questions

  • How long it lasts in the body (pharmacokinetics). A half-life (the time it takes for half a dose to clear) of about 2 hours was measured in healthy men after a 15-minute infusion into a vein. None of our sources measures it for injection under the skin. Tidepath doesn't chart its levels.
  • Whether results from a clinical study that gave it into a vein apply to injecting it under the skin.
  • Whether it builds muscle or improves sleep. It raises growth hormone, which is why it's grouped under both, but human studies haven't proven an effect on either.

Worth knowing

The FDA says a published study found serious health problems (serious adverse events), including death, when ipamorelin was given into a vein to get the stomach moving (gastric motility). The FDA's note doesn't name the study or say whether ipamorelin caused them. That study used a different route in different patients, so it doesn't show what injecting it under the skin does. It does show why having some safety data from people isn't the same as having evidence about that use.

More in Growth-hormone peptides